China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
67 hedge funds and large institutions have $1.11B invested in China Biologic Products Holdings, Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
9% more call options, than puts
Call options by funds: $9.38M | Put options by funds: $8.58M
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
18% less funds holding
Funds holding: 82 → 67 (-15)
19% less capital invested
Capital invested by funds: $1.38B → $1.11B (-$269M)
64% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.3M |
| 2 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
+$14.4M |
| 3 |
MAM
Myriad Asset Management
North Point,
Hong Kong
|
+$5.22M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
+$2.96M |
| 5 |
D.E. Shaw & Co
New York
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$220M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$70.7M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$70.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$33M |
| 5 |
Bank of New York Mellon
New York
|
-$14.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
New York State Common Retirement Fund
Albany,
New York
| – | -$456K | -5,699 | Closed |
|
|
PP
77
PDT Partners
New York
| – | -$409K | -5,107 | Closed |
|
|
GCIA
78
Gabelli & Co Investment Advisers
Rye,
New York
| – | -$352K | -4,400 | Closed |
|
|
YMRC
79
Yorktown Management & Research Company
Forest,
Virginia
| – | -$320K | -4,000 | Closed |
|
80
Jane Street
New York
| – | -$307K | -3,841 | Closed |
|
|
FRM
81
Fox Run Management
Greenwich,
Connecticut
| – | -$262K | -3,274 | Closed |
|
|
GF
82
Gabelli Funds
Rye,
New York
| – | -$232K | -2,900 | Closed |
|
83
Squarepoint
New York
| – | -$216K | -2,703 | Closed |
|
|
CSS
84
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$124K | -1,548 | Closed |
|
|
QT
85
Quantbot Technologies
New York
| – | -$36K | -456 | Closed |
|
86
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$9K | -110 | Closed |
|
|
OIA
87
Optimum Investment Advisors
Chicago,
Illinois
| – | -$8K | -100 | Closed |
|
|
RFC
88
Regions Financial Corp
Birmingham,
Alabama
| – | -$4K | -47 | Closed |
|
|
FGC
89
Financial Gravity Companies
Lakeway,
Texas
| – | +$147 | +2 | New |
|
CBPO Hedge Fund Activity: Q4 2018 in Review
67 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2018, worth a combined $1.11B — down 19% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CBPO and 8 opened new positions — a net loss of 14 holders — while 25 trimmed existing stakes and 24 added.
The largest buyer was Fidelity Investments, adding an estimated $21.3M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $220M sold.
- 67 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2018, down from 82 in Q3 2018.
- Funds reported $1.11B of China Biologic Products Holdings, Inc. stock for Q4 2018, down 19% quarter-over-quarter.
- 8 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2018 and 22 closed out, a net change of -14 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q4 2018 was Fidelity Investments, an estimated $21.3M added.
- The largest China Biologic Products Holdings, Inc. seller in Q4 2018 was Hillhouse Investment Management, an estimated $220M sold.
Based on aggregated 13F filings for Q4 2018.